What is Hepatitis B?
Hepatitis B is a viral infection caused by the hepatitis B virus (HBV), a DNA virus that attacks the liver and can lead to both acute and chronic disease, with chronic infection being the leading cause of liver cancer (hepatocellular carcinoma) worldwide. 1
The Virus and Transmission
HBV is a small DNA virus belonging to the Hepadnaviridae family with a 3.2 kb genome 2. It replicates through an RNA intermediate using reverse transcriptase, which gives it a higher mutation rate than typical DNA viruses 3. The virus is found in highest concentrations in blood, with lower levels in semen, vaginal secretions, wound exudates, and saliva 4.
Transmission occurs through:
- Percutaneous or mucous membrane exposure to infected blood or body fluids 4
- Sexual contact (the most common route in adults) 4, 5
- Perinatal transmission from mother to infant (vertical transmission) 1, 6
- Horizontal transmission during early childhood, including through premastication 4
- Injection drug use 4
HBV is more infectious and environmentally stable than other bloodborne pathogens like hepatitis C or HIV 4.
Disease Spectrum and Natural History
Acute vs. Chronic Infection
The outcome of HBV infection is heavily age-dependent 6:
- Infants infected perinatally: 90% develop chronic infection 6, 7
- Children under 5 years: 30-60% develop chronic infection 6, 7
- Adults: Only 5-10% develop chronic infection 6, 7
Approximately half of newly infected adults are asymptomatic, and only 1% develop acute liver failure 4.
Chronic Hepatitis B Phases
Chronic infection progresses through distinct clinical phases 8, 9:
- Immune tolerant phase: High viral load (HBV DNA), HBeAg positive, normal liver enzymes, minimal liver inflammation
- Immune active phase (chronic hepatitis B): Elevated liver enzymes, active liver inflammation, HBeAg positive or negative
- Inactive carrier state: Low/undetectable HBV DNA (<2,000 IU/mL), HBeAg negative, anti-HBe positive, normal liver enzymes
- Reactivation phase: Return of active disease after inactive carrier state
Global Burden and Complications
Worldwide, approximately 254-296 million people are chronically infected with HBV 1, 10, 8. The disease causes over 800,000 deaths annually, primarily from 1, 8:
- Liver cirrhosis (12-20% of chronic carriers develop cirrhosis) 8
- Hepatocellular carcinoma (HCC) - HBV is responsible for ~50% of HCC cases globally 8
- Hepatic decompensation
Once cirrhosis develops, the 5-year incidence of HCC is 10% 8. Among those with chronic infection, 15-25% will die prematurely from cirrhosis or liver cancer 4.
Diagnosis
Key diagnostic markers include 9, 11:
- HBsAg (hepatitis B surface antigen): Indicates active infection; persistence >6 months defines chronic infection
- HBeAg (hepatitis B e antigen): Marker of high viral replication
- Anti-HBc (antibody to core antigen): IgM indicates acute infection; total anti-HBc indicates past or current infection
- Anti-HBs (antibody to surface antigen): Indicates immunity from vaccination or resolved infection
- HBV DNA: Quantifies viral load; critical for treatment decisions
- ALT/AST levels: Assess liver inflammation
- Liver biopsy: Evaluates disease severity and fibrosis stage
Prevention
Vaccination is the most effective prevention strategy 8, 7:
- Recommended for all newborns, ideally within 12 hours of birth 6
- Global birth dose coverage reached 84% by 2015 8
- Vaccination has reduced chronic infection in children under 5 from 4.7% to 1.3% 8
For infants born to HBsAg-positive mothers 6:
- Administer hepatitis B vaccine AND hepatitis B immune globulin (HBIG) 0.5 mL within 12 hours of birth
- Complete the vaccine series at 1 month and 6 months
- This prevents >90% of perinatal infections 6
Treatment Overview
Two main categories of therapy exist 12:
- Interferons (standard or pegylated interferon alfa): Immunomodulators with finite treatment duration
- Nucleos(t)ide analogues (NAs): Direct-acting antivirals including entecavir, tenofovir (TDF/TAF), lamivudine, adefovir, telbivudine
Current treatment goals 8:
- Suppress viral replication to lowest possible levels
- Normalize liver enzymes
- Halt progression to cirrhosis and HCC
- Achieve "functional cure" (HBsAg loss), though this occurs in <5% with current therapies 8
Recent evidence strongly supports earlier and broader treatment initiation 1, 10. The 2025 guidelines emphasize that HBV-induced carcinogenic mechanisms are active throughout all infection phases, not just during advanced disease, making the case for treating a broader spectrum of patients to prevent cancer development 1.
Critical Gaps in Care
Major challenges include 1, 10:
- Only 10% of infected persons worldwide know their status 1
- In the US, only 15% know their status and only 5% receive treatment 1
- Current complex treatment criteria exclude many who could benefit from therapy 1, 10
- HBV cannot be fully eradicated due to persistent cccDNA in hepatocyte nuclei 12
The WHO goal is to eliminate viral hepatitis as a public health threat by 2030 1, 13, requiring expanded screening, vaccination, and treatment access.